Why the study?
Does M6434 improve blood pressure and orthostatic index compared to midodrine in rat models of hypotension?
Does M6434 improve blood pressure and orthostatic index compared to midodrine in rat models of hypotension?
M6434 is a potent alpha-1 adrenoceptor agonist that demonstrates superior anti-hypotensive effects compared to midodrine in rat models.
M6434 merits further preclinical development; leaves open translation to human orthostatic hypotension.
The anti-hypotensive effects of M6434 were evaluated and compared with those of other orally active sympathomimetics in rats. Oral administration of M6434 (0.5-2.0 mg/kg) and midodrine (1.0-5.0 mg/kg) also produced a dose-related increase in mean arterial pressure in normotensive rats. The pressor effect of M6434 was about 4 times more potent than that of midodrine. Both M6434 and midodrine caused a dose-dependent decrease in heart rate. The pressor effect of M6434 (1.0 mg/kg) did not diminish after its repeated administration for 7 days. The pretreatment with M6434 (0.5-1.0 mg/kg) and midodrine (2.0-5.0 mg/kg) improved the orthostatic index in the experimental model of postural hypotension in rats. The effect of M6434 on postural hypotension was about 5 times more potent than that of midodrine. Intravenously injected M6434 (3-300 micrograms/kg) produced a dose-dependent increase in the blood pressure of pithed rats. These results suggest that M6434 possesses a potent antihypotensive activity which is superior to that of midodrine, and M6434 may be useful in the treatment of essential and postural hypotension.
No takes yet. Share an insight, caveat, or question.
Dabasaki et al. (1992) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: